Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | February 06, 2019 | February 08, 2019 |
| Kronos Bio, Inc.KRON · Entity 78257 | Director | October 14, 2020 | October 16, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | March 03, 2021 | March 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,887,225 |
Ending reported balance
After 2019-02-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-06 · Grant · Acquired 7,745 · Balance 2,885,507 F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 2 · 2019-02-06 · Grant · Acquired 15,505 · Balance 2,901,012 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 3 · 2019-02-06 · Tax withholding · Disposed 13,787 · Balance 2,887,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
Kronos Bio, Inc.
Report date October 14, 2020 · Filed October 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,952,364 |
Last balance in matching sequence
After 2020-10-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-10-14 · Conversion · Acquired 914,333 · Balance 914,333 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 2 · 2020-10-14 · Conversion · Acquired 756,971 · Balance 1,671,304 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 3 · 2020-10-14 · Conversion · Acquired 205,260 · Balance 1,876,564 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 4 · 2020-10-14 · Purchase · Acquired 75,800 · Balance 1,952,364 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-14 · Conversion · Disposed 866,667 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-14 · Conversion · Disposed 717,509 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2022-02-20 | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-14 · Conversion · Disposed Not disclosed · Balance 0 F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Sarepta Therapeutics, Inc.
Report date March 03, 2021 · Filed March 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,913 |
Reported balance
After 2021-03-03 transaction · row 1
1 source rowRow 1 · 2021-03-03 · Grant · Acquired 2,726 · Balance 7,913 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.11 · Expires 2031-03-03 | Direct | 5,518 |
Reported balance
After 2021-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-03 · Grant · Acquired 5,518 · Balance 5,518 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 03, 2014 Filed Feb 5, 2014 23:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 49,000 | $80.21 | $3,930,226.30 |
DisclosureSEC source: 0001179110-14-002082 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,289,492 F4 · price: Sale prices reported for the transactions reported here range from $79.76 to $80.75. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 03, 2014 Filed Feb 5, 2014 23:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 58,400 | $79.05 | $4,616,724.40 |
DisclosureSEC source: 0001179110-14-002082 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,338,492 F3 · price: Sale prices reported for the transactions reported here range from $78.70 to $79.63. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| February 03, 2014 Filed Feb 5, 2014 23:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 140,625 | $8.01 | $1,125,703.13 |
DisclosureSEC source: 0001179110-14-002082 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,396,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 5, 2014 01:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock option (right to buy) · Derivative | 162,260 | $0.00 Strike: $80.65 | $0.00 |
DisclosureSEC source: 0001179110-14-001948 · edgar.xml · derivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,260 Underlying: Common Stock · 162,260 shares Expires 2024-02-01 F1 · derivative.exercise_date: The options have a four year vesting schedule. 25% of the options will vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 43,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001416 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,256,267 F2 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on February 1, 2013. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2015. Read SEC document |
| January 23, 2014 Filed Jan 27, 2014 23:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 78,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-14-001416 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,213,121 F1 · shares: Represents shares of the Issuer's common stock subject to a specific tranche of the performance share award made to the Reporting Person on January 26, 2012. Such tranche of shares was subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was deemed satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be actually issued to the Reporting Person until such individual satisfies the applicable service-vesting requirement by continuing in the Issuer's employ through December 31, 2014. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 140,625 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0001179110-14-000525 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,546,883 Underlying: Common Stock · 140,625 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 140,625 | $75.02 | $10,550,179.69 |
DisclosureSEC source: 0001179110-14-000525 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F3 · price: Sale prices reported for the transactions reported here range from $74.52 to $75.43. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| January 02, 2014 Filed Jan 6, 2014 22:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 140,625 | $8.01 | $1,125,703.13 |
DisclosureSEC source: 0001179110-14-000525 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,197,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2013 Filed Dec 4, 2013 20:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-017395 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| December 02, 2013 Filed Dec 4, 2013 20:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 17,742 | $74.79 | $1,326,862.08 |
DisclosureSEC source: 0001179110-13-017395 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F4 · price: Sale prices reported for the transactions reported here range from $74.63 to $74.85. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 02, 2013 Filed Dec 4, 2013 20:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 264,500 | $74.23 | $19,633,835.00 |
DisclosureSEC source: 0001179110-13-017395 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,074,863 F3 · price: Sale prices reported for the transactions reported here range from $73.62 to $74.60. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| December 02, 2013 Filed Dec 4, 2013 20:55 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-017395 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2013 Filed Nov 6, 2013 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-016221 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,242 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| November 01, 2013 Filed Nov 6, 2013 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 282,242 | $70.83 | $19,990,213.01 |
DisclosureSEC source: 0001179110-13-016221 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F3 · price: Sale prices reported for the transactions reported here range from $70.46 to $71.39. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| November 01, 2013 Filed Nov 6, 2013 01:14 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-016221 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2013 Filed Oct 3, 2013 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-015177 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 564,484 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| October 01, 2013 Filed Oct 3, 2013 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 282,242 | $62.70 | $17,696,545.18 |
DisclosureSEC source: 0001179110-13-015177 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F3 · price: Sale prices reported for the transactions reported here range from $62.32 to $63.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| October 01, 2013 Filed Oct 3, 2013 20:10 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-015177 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2013 Filed Sep 5, 2013 23:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-013917 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 846,726 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| September 03, 2013 Filed Sep 5, 2013 23:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 14,500 | $61.45 | $890,990.20 |
DisclosureSEC source: 0001179110-13-013917 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F4 · price: Sale prices reported for the transactions reported here range from $61.36 to $61.55. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 03, 2013 Filed Sep 5, 2013 23:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 267,742 | $60.95 | $16,318,500.06 |
DisclosureSEC source: 0001179110-13-013917 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,071,621 F3 · price: Sale prices reported for the transactions reported here range from $60.35 to $61.35. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| September 03, 2013 Filed Sep 5, 2013 23:44 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-013917 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2013 Filed Aug 5, 2013 20:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-012639 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,128,968 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| August 01, 2013 Filed Aug 5, 2013 20:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 36,242 | $62.04 | $2,248,341.33 |
DisclosureSEC source: 0001179110-13-012639 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F4 · price: Sale prices reported for the transactions reported here range from $62.00 to $62.07. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 01, 2013 Filed Aug 5, 2013 20:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 246,000 | $61.55 | $15,141,398.40 |
DisclosureSEC source: 0001179110-13-012639 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,093,363 F3 · price: Sale prices reported for the transactions reported here range from $60.99 to $61.99. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| August 01, 2013 Filed Aug 5, 2013 20:08 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-012639 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 21:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-011559 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,411,210 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 21:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 20,800 | $52.64 | $1,094,837.12 |
DisclosureSEC source: 0001179110-13-011559 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F4 · price: Sale prices reported for the transactions reported here range from $52.57 to $52.79. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 21:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 261,442 | $51.95 | $13,582,983.81 |
DisclosureSEC source: 0001179110-13-011559 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,077,921 F3 · price: Sale prices reported for the transactions reported here range from $51.56 to $52.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| July 01, 2013 Filed Jul 3, 2013 21:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-011559 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2013 Filed Jun 5, 2013 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-009773 · edgar.xml · derivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,693,452 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| June 03, 2013 Filed Jun 5, 2013 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,542 | $54.59 | $193,352.11 |
DisclosureSEC source: 0001179110-13-009773 · edgar.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F6 · price: Sale prices reported for the transactions reported here range from $54.55 to $54.59. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 03, 2013 Filed Jun 5, 2013 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 24,800 | $53.99 | $1,339,001.60 |
DisclosureSEC source: 0001179110-13-009773 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,060,663 F5 · price: Sale prices reported for the transactions reported here range from $53.46 to $54.44. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 03, 2013 Filed Jun 5, 2013 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 225,700 | $52.80 | $11,916,598.88 |
DisclosureSEC source: 0001179110-13-009773 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,085,463 F4 · price: Sale prices reported for the transactions reported here range from $52.43 to $53.41. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 03, 2013 Filed Jun 5, 2013 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 28,200 | $51.91 | $1,463,918.40 |
DisclosureSEC source: 0001179110-13-009773 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,311,163 F3 · price: Sale prices reported for the transactions reported here range from $51.42 to $52.42. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| June 03, 2013 Filed Jun 5, 2013 22:36 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-009773 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2013 Filed May 3, 2013 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-007717 · edgar.xml · derivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,975,694 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| May 01, 2013 Filed May 3, 2013 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 282,242 | $50.17 | $14,160,956.09 |
DisclosureSEC source: 0001179110-13-007717 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F3 · price: Sale prices reported for the transactions reported here range from $49.88 to $50.62. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| May 01, 2013 Filed May 3, 2013 22:15 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-007717 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 20:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-006354 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,257,936 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 20:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 181,242 | $48.47 | $8,784,564.13 |
DisclosureSEC source: 0001179110-13-006354 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 F4 · price: Sale prices reported for the transactions reported here range from $48.15 to $49.15. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 20:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 101,000 | $48.01 | $4,848,969.60 |
DisclosureSEC source: 0001179110-13-006354 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,238,363 F3 · price: Sale prices reported for the transactions reported here range from $47.92 to $48.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| April 01, 2013 Filed Apr 3, 2013 20:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-006354 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,339,363 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 55,311 | $45.40 | $2,511,119.40 |
DisclosureSEC source: 0001179110-13-004728 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,057,121 Read SEC document |
| March 06, 2013 Filed Mar 8, 2013 22:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 106,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-13-004728 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,112,432 F1 · shares: Vesting of performance share awards on March 6, 2013 Read SEC document |
| March 01, 2013 Filed Mar 5, 2013 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock option (right to buy) · Derivative | 282,242 | $0.00 Strike: $7.63 | $0.00 |
DisclosureSEC source: 0001179110-13-004248 · edgar.xml · derivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,540,178 Underlying: Common Stock · 282,242 shares Expires 2014-01-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested. Read SEC document |
| March 01, 2013 Filed Mar 5, 2013 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 67,535 | $43.43 | $2,932,754.65 |
DisclosureSEC source: 0001179110-13-004248 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,006,432 F4 · price: Sale prices reported for the transactions reported here range from $43.39 to $43.48. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 01, 2013 Filed Mar 5, 2013 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 214,707 | $43.05 | $9,243,308.12 |
DisclosureSEC source: 0001179110-13-004248 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,073,967 F3 · price: Sale prices reported for the transactions reported here range from $42.38 to $43.38. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. Read SEC document |
| March 01, 2013 Filed Mar 5, 2013 22:13 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 282,242 | $7.63 | $2,154,212.07 |
DisclosureSEC source: 0001179110-13-004248 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,288,674 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · balance_after: Amount of securities beneficially owned following the reported transaction includes 968 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on February 15, 2013. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.